The latest volume was: 0. FS Development in an 8-K filing announced that shareholders have approved the SPAC's proposed $216 million merger with Gemini Therapeutics. Accelerator/Incubator Insights. Merger Target: Gemini Therapeutics Industry: Age-related Macular Degeneration Therapy Pro Forma Market Capitalization: $479 million Gemini Therapeutics … Gemini Therapeutics, Inc. /DE is listed on the stock exchange with the ticker / Symbol GMTX, GMTX SPAC all time high was $16,64 and the lowest price in the last 52 week was: , the current GMTX stock price is $14,84. Company: Gemini Therapeutics. GMTX is currently in stage: 5. & SAN FRANCISCO--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration, and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger … Gemini Therapeutics, Inc., the resulting combined … Tananbaum’s last outing with a SPAC resulted in a successful merger with Gemini Therapeutics in the fall of 2020. GMTX has an overall market cap of: $672.281.538. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. International Investor Insights. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its business combination with FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Cambridge, Mass.-based Gemini merged with FS Development Corp., a special purpose acquisition company created by Foresite Capital. Gemini Therapeutics, Inc. /DE is primarely in the business of pharmaceutical preparations. Gemini Therapeutics and FS Development Corp. Genosity, Inc, a biotechnology company offering novel software and laboratory solutions to enable development and deployment of complex NGS assays, announced an agreement with Gemini Therapeutics to conduct molecular profiling in support of clinical trial patient selection and stratification for Gemini’s GEM103 program in age-related macular degeneration (AMD). The Life Sciences and Special Purpose Acquisition Companies (SPACs) teams advised Gemini Therapeutics on its definitive business combination agreement with FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital.. Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age … Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the completion of enrollment in its Phase 2a "ReGAtta" study. – January 7, 2021 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that GEM103, the Company’s investigational treatment for dry AMD, has been granted Fast Track designation by the United States Food and Drug Administration (FDA). Track story: Gemini Therapeutics Hits the Nasdaq Following SPAC Merger BioSpace and other headlines for Track Group Gemini Chief Executive Officer Jason Meyenburg pictured above. Insights . For financial reporting, their fiscal year ends on December 31st. FS Development Corp. (FSDC) to Combine with Gemini Therapeutics Oct 15, 2020 INTEL by Nicholas Alan Clayton Biotech firm Gemini Therapeutics announced this morning that it has entered into a definitive merger agreement with FS Development Corp. (NASDAQ:FSDC) that would give it a pro forma valuation of $265.6 million. Foresite Capital sponsored FS Development Corp. (NASDAQ:FSDC) and precision medicine company Gemini Therapeutics have entered into a definitive merger agreement creating a … Investor Insights. Prospect Insights. Gemini Therapeutics, Inc. /DE is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. CAMBRIDGE, Mass. Stock analysis for Gemini Therapeutics Inc (FSDC) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Gemini is a clinical stage precision medicine company developing treatments for genetically… The vote was 10,861,619 shares in favor of the deal with 912,082 shares voted in opposition. This copy is for your personal, non-commercial use only. Foresite's previous SPAC, FS Development (FSDC; +24% from $10 offer price), went public in August 2020 and has a pending merger agreement with AMD biotech Gemini Therapeutics. Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. ex-10.3 5 ea128463ex10-3_fsdevelopment.htm parent support agreement, dated as of october 15, 2020, by and among fs development corp., gemini therapeutics, inc. fs development holdings, llc and certain supporting stockholders of fs development corp Gemini Therapeutics Hits the Nasdaq Following SPAC Merger https://hubs.li/H0Gc34V0 The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX. Gemini Therapeutics Hits the Nasdaq Following SPAC Merger | BioSpace via: BioSpace Spacinsider counts 10 warrantless healthcare Spacs that have floated in Therapeutics Acquisition’s wake, although only one has found a deal: Foresite Capital announced a merger with Gemini Therapeutics last October, in an incredibly swift 64 days after its IPO. Photo courtesy of Gemini. See insights on Gemini Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Gemini Therapeutics And FS Development Corp Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused On Age-Related Macular Degeneration FS … Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration: 2020-10-15: Gemini Therapeutics and FS Development Corp. Gemini Therapeutics is now trading on the Nasdaq Exchange following its merger with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). A Route to Public Markets for Gemini Therapeutics Gemini Therapeutics , a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market (GMTX), becoming one of the latest life sciences companies to merge with a special purpose acquisition company (SPAC), which are all over Wall Street these days. Corporate VC Insights. Gemini Therapeutics fits this profile: it just initiated a Phase 2 study for it’s lead program, had raised $42M in prior financings, and was evaluating strategic options for going public. Merger Complete. Explore Gemini Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here! Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) by developing drugging strategies that are matched to specific genetic mutations found in patients with high clinical unmet need. The SPAC said 100 shares were redeemed. The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol GMTX. Gemini Therapeutics has 30 employees at their 1 location and $44.50 m in total funding,. CAMBRIDGE, Mass. Top CEOs 2019/2020.